Background: The principal symptoms of myasthenia gravis (MG), muscde weakness and fatigue due to impaired neuromuscular transmission, are caused by autoantibodies to the musde nicotinic acetylcholine receptor (AChR). The
INTRODUCTION
Myasthenia gravis (MG) is an autoimmune disorder of neuromuscular transmission. The presence of high-affinity autoantibodies directed against the muscle nicotinic acetylcholine recep-tor (AChR) in more than 90% of MG patients suggests the involvement of humoral responses in disease pathogenesis (1, 2) . In addition, although the precise role of cell-mediated responses in MG remains to be elucidated, several lines of evidence indicate an important contribution by T lymphocytes: (i) frequent incidence of medullary lymphofollicular hyperplasia in MG thymi (3); (ii) amelioration of myasthenic state following thymectomy (3); (iii) presence of T D. Gigliotti et al.: TCR Vf8 Gene Usage in Myasthenia Gravis lymphocytes exhibiting an impaired production of cytokines, such as interleukin-2 (IL-2) and interferon--y (IFNy), as measured in vitro (4); (iv) identification of AChR-specific CD4+ T cells derived from peripheral blood of MG patients (5, 6) ; and, interestingly, (v) mitigation of symptoms of disease by treatment with anti-CD4 monoclonal antibody (7) .
During early events in thymic maturation processes, T cells acquire functional heterodimeric a/1f T cell receptors (TCRs) (8) . The actual specificity of these receptors results from somatic recombination of one of the variable (V) and joining (J) exons, and of one of the V, diversity (D), and J exons encoding the variable domains of a-and p3-chains, respectively. Depending on the nature of the antigen, interaction with the TCR will involve different parts of the variable domains. A group of protein molecules, defined as superantigens (SA), have the potential of activating a substantial fraction of T cells (5-30%) through interaction with specific target sequences of distinct VP3 gene family products (reviewed in Refs. [9] [10] [11] [12] . As opposed to conventional presentation of nominal antigen, the powerful T cell activation by SA occurs in the absence of protein processing via binding to monomorphic portions of MHC class II molecules, outside the peptide-binding groove area (13) . This polyclonal, albeit selective, activation of T lymphocytes may eventually result in peripheral termination of the state of tolerance to particular self antigens (1 1, 12) . A potential connection between SA and autoimmune diseases is thus intriguing because of the microbial origin of many of these antigens and the frequently reported relationship between infection and onset of human autoimmune illnesses (14) .
In recent years, several T cell-mediated autoimmune disorders have been studied in an attempt to identify disease-associated diverging distribution patterns of TCR expression (15) (16) (17) (18) . Analyses of T cell expansions in peripheral blood of MG patients using a panel of Va and VP3 gene product-specific monoclonal antibodies have been performed by several groups (19) , including our own (20 
Statistical Analysis
The nonparametric Wilcoxon-Mann-Whitney two-tailed test was used. (33) .
Superantigen-activated T cell subsets expressing the relevant V,3(s) have as one additional characteristic distinguishing them from nominal antigen-driven oligoclonal expansions: a broad, normal relative expression of J,B multigene family members. We analyzed the V131-overexpressing T lymphocytes in MG patients and determined that they behaved in concordance with superantigen activation in that their usage of Jo3 gene segments was equal in distribution pattern to normal control V,B1 + T cells. Hence, we reach the tentative conclusion that MG encompasses, as one reproducible element of the disease, a biased overusage of VP31, Vf313.2, Vf17, and Vf320 exons within both CD4+ and CD8+ T cell subsets. We are unaware of any presently defined SA that selectively targets Vo31-, Vo113.2-, Vol17-, and V,B20-expressing T cells. The driving molecule is thus likely to be a novel SA, which is yet to be defined, and a search for this hypothetical molecule has now been initiated.
A problem associated with data indicating positive correlation between two parameters (in this case, induction/maintenance of the MG disease and overrepresentation of TCR Vf3s), relates to the question of whether the actual connection represents a causal or a consequential relationship. Nevertheless, our identification of a positively disease-associated overrepresentation of select Vf3s in the T cell pool within MG patients may provide new therapeutic strategies of intervention for myasthenia gravis.
